Sugi Predict

Sugi Predict / Compounds / SCHEMBL20840280

SCHEMBL20840280

SCHEMBL20840280

C#CCOCCOCCOCCOCCNC(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.45
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ CA12 O43570 5/20 0.41
▸ CA1 P00915 5/20 0.41
▸ CA2 P00918 5/20 0.41
▸ CA9 Q16790 5/20 0.41
▸ MAOA P21397 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ IDO1 P14902 1/20 0.39
▸ BCHE P06276 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ EPHX1 P07099 1/20 0.38
▸ ADRB2 P07550 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ SUCNR1 Q9BXA5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22276586 1.00 TDP1 (0.45) TDP1MEN1KMT2AGAACA12
SCHEMBL19451386 1.00 TDP1 (0.45) TDP1MEN1KMT2AGAACA12
SCHEMBL13759230 1.00 TDP1 (0.45) TDP1MEN1KMT2AGAACA12
SCHEMBL30484826 1.00 TDP1 (0.45) TDP1MEN1KMT2AGAACA12
SCHEMBL31111448 1.00 TDP1 (0.45) TDP1MEN1KMT2AGAACA12
SCHEMBL612182 0.97 TDP1 (0.47) TDP1MEN1KMT2AGAACA12
SCHEMBL25721633 0.96 TDP1 (0.42) TDP1MEN1KMT2AGAACA12
SCHEMBL22796847 0.94 TDP1 (0.46) TDP1MEN1KMT2AGAACA12
SCHEMBL23789774 0.92 TDP1 (0.39) TDP1MEN1KMT2AGAACA12
SCHEMBL23662963 0.92 TDP1 (0.39) TDP1MEN1KMT2AGAACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260041686-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2026-02-12 — — US disclosed
US-12540127-B2 CRBN ligands and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-03 — — US disclosed
US-12521393-B2 Cytotoxicity targeting chimeras for CCR2-expressing cells GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-01-13 — — US disclosed
EP-4640280-A2 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-10-29 — — EP disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4384223-B1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2025-10-01 — — EP disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-4608807-A1 PROTEIN DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-03 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250136722-A1 CYTOTOXICITY TARGETING CHIMERAS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-05-01 — — US disclosed
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 — — CN disclosed
US-20200377469-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2020-12-03 — — US disclosed
US-20200377469-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2020-12-03 — — US disclosed
EP-3731869-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2020-11-04 — — EP disclosed
WO-2020152067-A1 HETEROCYCLIC DERIVATIVES MERCK PATENT GMBH (DE) 2020-07-30 — — WO disclosed
EP-3684366-A1 CRBN LIGANDS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2020-07-29 — — EP disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
WO-2019060693-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2019-03-28 — — WO disclosed
WO-2019060693-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2019-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377469-A1 CRBN LIGANDS AND USES THEREOF CRBN, CRKL, ERBB3 TDP1 3254/4885MEN1 2201/4885KMT2A 2436/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TDP1 236/4885MEN1 4055/4885KMT2A 445/4885
US-20260041686-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS CCR2, CCR1, CCRL2 TDP1 1585/4885MEN1 4141/4885KMT2A 1711/4885
US-20250136722-A1 CYTOTOXICITY TARGETING CHIMERAS HAVCR2, CD47, CYTH3 TDP1 2820/4885MEN1 3723/4885KMT2A 3960/4885
US-12540127-B2 CRBN ligands and uses thereof CRBN, NR2C2, NR2E3 TDP1 4593/4885MEN1 3927/4885KMT2A 2126/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TDP1 236/4885MEN1 4055/4885KMT2A 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.